<p>Thor Wagner of Seattle Children's Hospital in the U.S. will use high-throughput single-cell screening of activated B-cells from HIV patients on antiretroviral therapy in an effort to identify antibodies that bind specifically to HIV-infected cells. These antibodies could be used to develop antibody drug conjugates to kill HIV-infected cells.</p>


Thor Wagner of Seattle Children's Hospital in the U.S. will use high-throughput single-cell screening of activated B-cells from HIV patients on antiretroviral therapy in an effort to identify antibodies that bind specifically to HIV-infected cells. These antibodies could be used to develop antibody drug conjugates to kill HIV-infected cells.